Envestnet Asset Management Inc. cut its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 9.8% in the fourth quarter, HoldingsChannel reports. The fund owned 35,429 shares of the company’s stock after selling 3,835 shares during the period. Envestnet Asset Management Inc.’s holdings in Ionis Pharmaceuticals were worth $1,338,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its holdings in Ionis Pharmaceuticals by 722.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,755 shares of the company’s stock worth $520,000 after acquiring an additional 10,325 shares during the period. Gateway Investment Advisers LLC boosted its stake in Ionis Pharmaceuticals by 1.9% during the 4th quarter. Gateway Investment Advisers LLC now owns 51,174 shares of the company’s stock worth $1,933,000 after acquiring an additional 975 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Ionis Pharmaceuticals by 22.6% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 153,000 shares of the company’s stock valued at $5,699,000 after purchasing an additional 28,224 shares during the period. Algert Global LLC grew its holdings in Ionis Pharmaceuticals by 144.7% during the third quarter. Algert Global LLC now owns 60,937 shares of the company’s stock valued at $2,695,000 after purchasing an additional 36,037 shares during the period. Finally, Quantamental Technologies LLC bought a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $305,000. 87.32% of the stock is currently owned by institutional investors and hedge funds.
Ionis Pharmaceuticals Price Performance
NASDAQ:IONS opened at $42.28 on Wednesday. The stock’s 50-day simple moving average is $36.10 and its 200 day simple moving average is $38.03. The company has a debt-to-equity ratio of 2.42, a quick ratio of 9.72 and a current ratio of 9.81. The company has a market cap of $6.05 billion, a P/E ratio of -18.30 and a beta of 0.54. Ionis Pharmaceuticals, Inc. has a 52-week low of $32.69 and a 52-week high of $48.82.
Analysts Set New Price Targets
IONS has been the subject of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $65.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, February 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 23rd. Barclays decreased their price objective on Ionis Pharmaceuticals from $40.00 to $37.00 in a research report on Thursday, May 4th. BMO Capital Markets cut their price target on shares of Ionis Pharmaceuticals from $70.00 to $67.00 and set an “outperform” rating on the stock in a research note on Thursday, February 23rd. Finally, VNET Group reissued a “maintains” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, May 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $46.64.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T.
- Get a free copy of the StockNews.com research report on Ionis Pharmaceuticals (IONS)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating).
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.